ACTO Integrates AI Roleplay Solution with Veeva Vault CRM
ACTO Technologies has launched its AI-driven roleplay solution, CxZone, within Veeva Vault CRM via X-Pages to assist life sciences field teams.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
ACTO Technologies has launched its AI-driven roleplay solution, CxZone, within Veeva Vault CRM via X-Pages to assist life sciences field teams.
Vivos Therapeutics reported a Q3 loss of $0.07 per share, beating consensus estimates of $0.30 loss by 76.67%. Revenue came in at $6.41 million, surpassing estimates by 17.15%, though down from $6.78 million year-ago. The stock has declined 95.2% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Veeva Systems announced it will report its financial results for the third quarter ending October 31, 2026, after market close on December 3, 2026.
Wells Fargo analyst Stan Berenshteyn has maintained an Overweight/Buy rating on Veeva Systems and increased the price target to $400.
Devia, an agentic AI platform spun out from Visium, officially launched to help biopharma companies, CDMOs, and CROs manage pharmaceutical deviations. The platform automates deviation investigation workflows from initial report through root cause analysis and CAPA, with built-in traceability for regulatory compliance. After a year of pilot testing with quality teams, Devia claims to have halved investigation time while integrating with existing validated systems like TrackWise and Veeva Vault QMS.
Several financial institutions, including Canaccord Genuity, BTIG, and Truist Securities, updated their price targets for Veeva Systems on November 9, 2026.